{"id":63528,"title":"A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.","abstract":"","date":"2014-04-09","categories":"Hemic and Lymphatic Diseases","split":"train","url":"http://www.ncbi.nlm.nih.gov/pubmed/24429336","annotations":[{"name":"Dexamethasone","weight":0.327124,"wikipedia_article":"http://en.wikipedia.org/wiki/Dexamethasone"},{"name":"Bortezomib","weight":0.327124,"wikipedia_article":"http://en.wikipedia.org/wiki/Bortezomib"},{"name":"Lenalidomide","weight":0.247222,"wikipedia_article":"http://en.wikipedia.org/wiki/Lenalidomide"},{"name":"Drug metabolism","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Drug_metabolism"},{"name":"Trial","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Trial"},{"name":"Multiple myeloma","weight":0.0163827,"wikipedia_article":"http://en.wikipedia.org/wiki/Multiple_myeloma"},{"name":"Phase (matter)","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Phase_(matter)"}]}
